FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 175.6

Change

+0.81 (+0.46)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.39 (-0.26%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-0.27 (-0.38%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-0.07 (-0.06%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.55 (-1.68%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.24 (-0.97%)

USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

-0.53 (-1.31%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-1.07 (-1.10%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.09 (-0.29%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.44 (-0.67%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-1.84%)

USD 0.01B

ETFs Containing FBT

FHM:CA 99.89 % 0.78 %

N/A

N/A
FBT:CA First Trust NYSE Arca Bio.. 0.00 % 0.00 %

-0.45 (-1.45%)

CAD 1.83M

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.10% 62% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.10% 62% D 51% F
Trailing 12 Months  
Capital Gain 25.83% 71% C- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.83% 67% D+ 64% D
Trailing 5 Years  
Capital Gain 28.00% 38% F 61% D-
Dividend Return 1.61% 39% F 4% F
Total Return 29.61% 38% F 51% F
Average Annual (5 Year Horizon)  
Capital Gain 1.20% 33% F 38% F
Dividend Return 1.53% 33% F 30% F
Total Return 0.33% 42% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 12.06% 95% A 74% C
Risk Adjusted Return 12.71% 38% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.